Zacks: Analysts Anticipate Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) to Announce -$0.49 EPS

Wall Street analysts expect Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) to post ($0.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.36). Verrica Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which suggests a negative year over year growth rate of 40%. The firm is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Verrica Pharmaceuticals will report full-year earnings of ($2.04) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.79). For the next financial year, analysts anticipate that the business will post earnings of ($1.52) per share, with EPS estimates ranging from ($2.26) to ($1.05). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Verrica Pharmaceuticals.

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) last announced its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13.

A number of equities analysts have weighed in on VRCA shares. Needham & Company LLC lowered their price target on Verrica Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. HC Wainwright restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Monday, March 7th. Zacks Investment Research upgraded Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Friday, May 13th. Brookline Capital Acquisition initiated coverage on Verrica Pharmaceuticals in a report on Thursday, March 10th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Brookline Capital Management restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Thursday, March 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verrica Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $16.89.

Several hedge funds have recently modified their holdings of VRCA. BlackRock Inc. boosted its stake in shares of Verrica Pharmaceuticals by 23.1% in the fourth quarter. BlackRock Inc. now owns 794,466 shares of the company’s stock valued at $7,278,000 after buying an additional 149,248 shares during the period. Morgan Stanley raised its position in Verrica Pharmaceuticals by 2,540.4% during the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock valued at $1,380,000 after purchasing an additional 117,442 shares in the last quarter. Millennium Management LLC raised its position in Verrica Pharmaceuticals by 466.6% during the fourth quarter. Millennium Management LLC now owns 94,220 shares of the company’s stock valued at $863,000 after purchasing an additional 77,590 shares in the last quarter. Geode Capital Management LLC raised its position in Verrica Pharmaceuticals by 11.8% during the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock valued at $2,975,000 after purchasing an additional 25,089 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Verrica Pharmaceuticals by 182.9% during the fourth quarter. Bank of America Corp DE now owns 28,451 shares of the company’s stock valued at $260,000 after purchasing an additional 18,393 shares in the last quarter. Institutional investors and hedge funds own 34.58% of the company’s stock.

Shares of NASDAQ VRCA opened at $5.94 on Monday. The business’s 50 day moving average price is $7.42 and its two-hundred day moving average price is $8.59. The company has a market cap of $163.46 million, a PE ratio of -3.81 and a beta of 1.96. Verrica Pharmaceuticals has a twelve month low of $5.20 and a twelve month high of $14.79.

Verrica Pharmaceuticals Company Profile (Get Rating)

Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

Featured Stories